Literature DB >> 6402310

Phorbol 12,13-dibutyrate (P(Bu)2)-treated human blood mononuclear cells bind to each other.

M Patarroyo, P Biberfeld, E Klein, G Klein.   

Abstract

Treatment of human blood mononuclear cells with nanomolar concentrations of phorbol 12,13-dibutyrate (P(Bu)2) induced their aggregation. The phenomenon was seen within a few minutes and reached its maximum manifestation after 20 min. At this time, 20-30% of unfractionated and nylon wool-passed mononuclear leukocytes were in the aggregates. The influence of pretreatment with 2-deoxyglucose, NaN3, EDTA, cyclohexamide, or incubation at 4 degrees C on the phenomenon indicated that it is energy and temperature dependent, requires the presence of extracellular divalent cations, and is independent of protein synthesis. Nonaggregating 2-deoxyglucose-and NaN3-pretreated cells could still bind [3H]P(Bu)2 which rules out the possibility that the phorbol ester molecule acts as a bridge between the aggregated cells. Seventeen percent of the P(Bu)2-treated T-cell population bound untreated autologous and allogeneic cells. The binding property has a certain species specificity because only 4% of the cells interacted with mouse lymphocytes. At the ultrastructural level, the intercellular binding showed broad areas of surface contact (both between lymphocytes and lymphocyte-monocyte) and "trapping" by surface processes was not seen. Aggregated cells did not show cytopathogenic changes.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6402310     DOI: 10.1016/0008-8749(83)90313-1

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  2 in total

1.  T-cell adhesion to endothelial cells in systemic lupus erythematosis.

Authors:  D O Haskard; D Cavender; D Maliakkal; M Ziff
Journal:  Rheumatol Int       Date:  1989       Impact factor: 2.631

2.  Expression of ICAM-1 (CD54) on normal and leukaemic B cells: implication for the mixed lymphocyte reaction.

Authors:  M R Padros; M I Noli; L Fainboim
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.